Rosuvastatin and the statin wars--the way to peace.
Meyboom
Ronald H B
RH
Department of Pharmacoepidemiology, Faculty of Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, Netherlands. r.meyboom@who-umc.org
Edwards
I Ralph
IR
D016907:Adverse Drug Reaction Reporting Systems; D004345:Drug Industry; D005062:European Union; D005464:Fluorobenzenes / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D040541:Marketing; D011358:Product Surveillance, Postmarketing; D011743:Pyrimidines / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced*; D000068718:Rosuvastatin Calcium; D012449:Safety; D013449:Sulfonamides / Q000009:adverse effects*; D006113:United Kingdom
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium